Advertisement
Home Tags Cancer: Lung

Tag: Cancer: Lung

The American Lung Association and the American Thoracic Society have established a website to guide implementation of lung cancer screening

Lung Cancer Screening Implementation Guide Developed

Implementation guide designed to increase levels of lung cancer screening for heavy smokers
Adverse events for immune checkpoint inhibitors used to treat non-small cell lung cancer may be more common in real-world settings than reported in the clinical trials that led to U.S. Food and Drug Administration approvals

Immunotherapy Side Effects May Be More Common Than Thought

Higher rates of adverse events observed for immune checkpoint inhibitors in real-world settings
For patients undergoing resection for non-small cell lung cancer

More Frequent Surveillance No Benefit After NSCLC Resection

More frequent postsurgical surveillance is not associated with improved survival
Existing tobacco control efforts will continue to reduce lung cancer mortality through 2065

Models Project 79 Percent Drop in Lung CA Mortality by 2065

Annual number of deaths expected to continue to decrease despite growth, aging of U.S. population
The use of angiotensin-converting enzyme inhibitors is associated with an increased risk for lung cancer compared with angiotensin receptor blockers

Angiotensin-Converting Enzyme Inhibitors May Up Lung CA Risk

Higher risk seen with ACEIs versus angiotensin receptor blockers; risk linked to duration of use
Durvalumab results in significantly longer overall survival than placebo among patients with stage III

Durvalumab Extends Survival in Stage III Non-Small Cell Lung CA

Both overall and progression-free survival longer with durvalumab than with placebo
Thermal ablation is a safe

Thermal Ablation Acceptable for Early Lung Cancer

Regarding overall survival, thermal ablation non-inferior to radiation for primary treatment
Integration of plasma next-generation sequencing into the routine management of metastatic non-small cell lung cancer results in an increase in the detection of therapeutically targetable mutations

Plasma-Based Genotyping Aids Targeted Tx of Metastatic NSCLC

Most patients who received targeted therapy based on plasma result achieved clinical response
Among patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who have not previously received an ALK inhibitor

In NSCLC, Longer Survival With Brigatinib Than Crizotinib

Longer progression-free survival in those with ALK-positive dz who did not previously take ALK inhibitor
An integrated plasma proteomics classifier

Integrated Classifier Identifies Benign Lung Nodules

Classifier integrates relative abundance of two plasma proteins with clinical risk prediction model